PDF(Pubmed)
Abstract：
Antibody-drug conjugates (ADCs) are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker. The monoclonal antibody targets tumor cells and transports small-molecule cytotoxic drugs for specific delivery and minimal off-target side effects. It is necessary for clinicians to understand the molecular characteristics and mechanisms of ADCs. Patients\' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. This consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.
摘要：
抗体-药物缀合物(ADC)是由通过接头与单克隆抗体连接的细胞毒性药物组成的靶向生物制剂。单克隆抗体靶向肿瘤细胞并转运小分子细胞毒性药物，用于特异性递送和最小的脱靶副作用。临床医生有必要了解ADC的分子特征和机制。患者的生存主要取决于适当的剂量和疗程，也取决于不良反应的适当管理。该共识提供了对市售ADC的系统评价，并进一步讨论了ADC的临床应用和管理。
